M
Monica Morrow
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 747
Citations - 45456
Monica Morrow is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Breast cancer & Mastectomy. The author has an hindex of 93, co-authored 676 publications receiving 39187 citations. Previous affiliations of Monica Morrow include University of North Carolina at Chapel Hill & Kettering University.
Papers
More filters
Journal ArticleDOI
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
A. Goldhirsch,E P Winer,A S Coates,R. D. Gelber,M Piccart-Gebhart,B. Thürlimann,H.-J. Senn,Kathy S. Albain,Fabrice Andre,Jonas Bergh,Hervé Bonnefoi,Denisse Bretel-Morales,Harold J. Burstein,Fatima Cardoso,M. Castiglione-Gertsch,Alan S. Coates,Marco Colleoni,Alberto Costa,Giuseppe Curigliano,Nancy E. Davidson,Angelo Di Leo,Bent Ejlertsen,John F. Forbes,Richard D. Gelber,Michael Gnant,Aron Goldhirsch,Pamela J. Goodwin,Paul E. Goss,Jay R. Harris,Daniel F. Hayes,Clifford A. Hudis,James N. Ingle,Jacek Jassem,Zefei Jiang,Per Karlsson,Sibylle Loibl,Monica Morrow,Moïse Namer,C. Kent Osborne,Ann H. Partridge,Frédérique Penault-Llorca,Charles M. Perou,Martine Piccart-Gebhart,Kathleen I. Pritchard,Emiel J. Th. Rutgers,Felix Sedlmayer,Vladimir Semiglazov,Z Shao,Ian E. Smith,Beat Thürlimann,Masakazu Toi,Andrew Tutt,Michael Untch,Giuseppe Viale,Toru Watanabe,Nicholas Wilcken,Eric P. Winer,William C. Wood +57 more
TL;DR: The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed and endorsed substantial new evidence on aspects of the local and regional therapies for early breast cancer, supporting less extensive surgery to the axilla and shorter durations of radiation therapy.
Journal ArticleDOI
Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: A randomized clinical trial
Armando E. Giuliano,Kelly K. Hunt,Karla V. Ballman,Peter D. Beitsch,Pat Whitworth,Peter W. Blumencranz,A. Marilyn Leitch,Sukamal Saha,Linda M. McCall,Monica Morrow +9 more
TL;DR: Among patients with limited SLN metastatic breast cancer treated with breast conservation and systemic therapy, the use of SLND alone compared with ALND did not result in inferior survival, and overall survival was the primary end point, with a noninferiority margin of a 1-sided hazard ratio of less than 1.3 indicating thatSLND alone is noninherited.
Journal ArticleDOI
The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial
Steven R. Cummings,Stephen Eckert,Kathryn A. Krueger,Deborah Grady,Trevor J. Powles,Jane A. Cauley,Larry Norton,Thomas Nickelsen,Nina H. Bjarnason,Monica Morrow,Marc E. Lippman,Dennis M. Black,Joan Ellen Glusman,Alberto Costa,V. Craig Jordan +14 more
TL;DR: The Multiple Outcomes of Raloxifene Evaluation (MORE) as discussed by the authors was a multicenter, randomized, double-blind trial, in which women taking raloxion hydrochloride or placebo were followed up for a median of 40 months at 180 clinical centers composed of community settings and medical practices in 25 countries, mainly in the United States and Europe.
Journal ArticleDOI
Revision of the American Joint Committee on Cancer Staging System for Breast Cancer
S. Eva Singletary,Craig Allred,Pandora Ashley,Lawrence W. Bassett,Donald A. Berry,Kirby I. Bland,Patrick I. Borgen,Gary Clark,Stephen B. Edge,Daniel F. Hayes,Lorie L. Hughes,Robert V. P. Hutter,Monica Morrow,David L. Page,Abram Recht,Richard L. Theriault,Ann D. Thor,Donald L. Weaver,H. Samuel Wieand,Frederick L. Greene +19 more
TL;DR: This revised staging system for breast carcinoma will be officially adopted for use in tumor registries in January 2003 and will be useful for the uniform accrual of outcome information in national databases.
Journal ArticleDOI
Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial.
Armando E. Giuliano,Linda M. McCall,Peter D. Beitsch,Pat Whitworth,Peter W. Blumencranz,A. Marilyn Leitch,Sukamal Saha,Kelly K. Hunt,Monica Morrow,Karla V. Ballman +9 more
TL;DR: Despite the potential for residual axillary disease after SLND, SLND without ALND can offer excellent regional control and may be reasonable management for selected patients with early-stage breast cancer treated with breast-conserving therapy and adjuvant systemic therapy.